The 1A29 monoclonal antibody specifically recognizes ICAM-1 which is also known as CD54. ICAM-1 is an 85 kDa type I transmembrane glycoprotein that is encoded by Icam1 (Intercellular adhesion molecule 1). It is expressed on vascular endothelium in lymphoid tissues, thymic stromal cells, peripheral blood monocytes, peritoneal macrophages and mast cells, dendritic cells, and weakly on peripheral lymphocytes and thymocytes. ICAM-1 is a ligand for LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18). Its expression is upregulated on activated lymphocytes and endothelial cells. 1A29 mAb inhibits Phorbol 12-Myristate 13-Acetate (PMA)-induced aggregation of phytohemagglutinin (PHA)-stimulated splenic blasts, as well as the adhesion of mitogen-stimulated blasts to high endothelial venule (HEV) cells and purified ICAM-1. The 1A29 antibody can reportedly inhibit leucocyte infiltration in in vivo systems, blocks induction of experimental allergic encephalomyelitis, and reduces NK-cell adhesion to tumor cells.
The antibody was conjugated to BD Horizon™ BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.